Cite
Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin
MLA
Yoganand Chillarige, et al. “Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin.” JAMA Internal Medicine, vol. 181, May 2021, p. 598. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....38357429db91ce85f1037fbdb4a35f84&authtype=sso&custid=ns315887.
APA
Yoganand Chillarige, Marie C. Bradley, David J. Graham, Stella G. Muthuri, Hana Lee, Shruti Parulekar, Xiyuan Wu, Jeffrey A. Kelman, Thomas E. MaCurdy, & Michael Wernecke. (2021). Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin. JAMA Internal Medicine, 181, 598.
Chicago
Yoganand Chillarige, Marie C. Bradley, David J. Graham, Stella G. Muthuri, Hana Lee, Shruti Parulekar, Xiyuan Wu, Jeffrey A. Kelman, Thomas E. MaCurdy, and Michael Wernecke. 2021. “Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin.” JAMA Internal Medicine 181 (May): 598. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....38357429db91ce85f1037fbdb4a35f84&authtype=sso&custid=ns315887.